Tag Archives: Avastin

In the Absence of Avastin: New Opportunity

By Jennifer Ringler | Published: February 2, 2011
written by guest blogger Ed Kissel, Vice President of Quantitative Analysis In July 2010, an advisory panel voted 12-1 to urge the FDA to withdraw the approved use of Avastin in metastatic HER2-negative breast cancer. As a result of this announcement, IntrinsiQ hypothesized that physicians would immediately decrease the use the drug in new [...]
Posted in Strategy | Also tagged | Leave a comment

Advisory Panel Rejects Avastin For Breast Cancer Treatment

By George Koroneos | Published: July 21, 2010
An FDA advisory panel on Tuesday voted 12–1 to discontinue Avastin (bevacizumab) as a treatment for advanced breast cancer due to post-market studies stating that the treatment does not to increase patient lifespan by any significant length of time. This is a huge problem for Roche who purchased the treatment as part of its merger with [...]
Posted in FDA, Safety | Also tagged , , , , , , , | 1 Comment

Avastin Gets Green Light for Use in Kidney Cancer

By George Koroneos | Published: August 5, 2009
Image by Getty Images via Daylife Score another win for Genentech and its cancer treatment Avastin (bevacizumab). On Monday, the biotech giant, now owned entirely by Roche, announced that FDA has approved the drug for kidney cancer. Avastin blocks new blood vessels from forming and supplying tumors with the nutrients they need to grow and spread to [...]
Posted in News | Also tagged , , , , , , | Leave a comment